Abstract
The systemic administration of drugs to treat bone diseases is often associated with poor uptake of the drug in the targeted tissue, potential systemic toxicity and suboptimal efficacy. In order to overcome these limitations, many micro- and nano-sized drug carriers have been developed for the treatment of bone pathologies that exhibit specific affinity for bone. Drug carriers can be functionalized with bone mineral seekers (BMS), creating a targeted drug delivery system (DDS) which is able to bind to bone and release therapeutics directly at the site of interest. This class of advanced DDS is of tremendous interest due to their strong affinity to bone, with great expectation to treat life-threatening bone disorders such as osteomyelitis, osteosarcoma or even osteoporosis. In this review, we first explain the mechanisms behind the affinity of several well-known BMS to bone, and then we present several effective approaches allowing the incorporation BMS into advanced DDS. Finally, we report the therapeutic applications of BMS based DDS under development or already established. Understanding the mechanisms behind the biological activity of recently developed BMS and their integration into advanced therapeutic delivery systems are essential prerequisites for further development of bone-targeting therapies with optimal efficacy.
| Original language | English |
|---|---|
| Pages (from-to) | 88-99 |
| Number of pages | 12 |
| Journal | Journal of controlled release |
| Volume | 269 |
| DOIs | |
| Publication status | Published - 10 Jan 2018 |
Fingerprint
Keywords
- UT-Hybrid-D
- Bone mineral seeker
- Bone seeking agent
- Drug delivery system
- Osteomyelitis
- Osteosarcoma
- Bisphosphonate
Cite this
}
Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics. / Rotman, S.G.; Grijpma, D.W.; Richards, R.G.; Moriarty, T.F.; Eglin, D.; Guillaume, O. (Corresponding Author).
In: Journal of controlled release, Vol. 269, 10.01.2018, p. 88-99.Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics
AU - Rotman, S.G.
AU - Grijpma, D.W.
AU - Richards, R.G.
AU - Moriarty, T.F.
AU - Eglin, D.
AU - Guillaume, O.
N1 - Elsevier deal
PY - 2018/1/10
Y1 - 2018/1/10
N2 - The systemic administration of drugs to treat bone diseases is often associated with poor uptake of the drug in the targeted tissue, potential systemic toxicity and suboptimal efficacy. In order to overcome these limitations, many micro- and nano-sized drug carriers have been developed for the treatment of bone pathologies that exhibit specific affinity for bone. Drug carriers can be functionalized with bone mineral seekers (BMS), creating a targeted drug delivery system (DDS) which is able to bind to bone and release therapeutics directly at the site of interest. This class of advanced DDS is of tremendous interest due to their strong affinity to bone, with great expectation to treat life-threatening bone disorders such as osteomyelitis, osteosarcoma or even osteoporosis. In this review, we first explain the mechanisms behind the affinity of several well-known BMS to bone, and then we present several effective approaches allowing the incorporation BMS into advanced DDS. Finally, we report the therapeutic applications of BMS based DDS under development or already established. Understanding the mechanisms behind the biological activity of recently developed BMS and their integration into advanced therapeutic delivery systems are essential prerequisites for further development of bone-targeting therapies with optimal efficacy.
AB - The systemic administration of drugs to treat bone diseases is often associated with poor uptake of the drug in the targeted tissue, potential systemic toxicity and suboptimal efficacy. In order to overcome these limitations, many micro- and nano-sized drug carriers have been developed for the treatment of bone pathologies that exhibit specific affinity for bone. Drug carriers can be functionalized with bone mineral seekers (BMS), creating a targeted drug delivery system (DDS) which is able to bind to bone and release therapeutics directly at the site of interest. This class of advanced DDS is of tremendous interest due to their strong affinity to bone, with great expectation to treat life-threatening bone disorders such as osteomyelitis, osteosarcoma or even osteoporosis. In this review, we first explain the mechanisms behind the affinity of several well-known BMS to bone, and then we present several effective approaches allowing the incorporation BMS into advanced DDS. Finally, we report the therapeutic applications of BMS based DDS under development or already established. Understanding the mechanisms behind the biological activity of recently developed BMS and their integration into advanced therapeutic delivery systems are essential prerequisites for further development of bone-targeting therapies with optimal efficacy.
KW - UT-Hybrid-D
KW - Bone mineral seeker
KW - Bone seeking agent
KW - Drug delivery system
KW - Osteomyelitis
KW - Osteosarcoma
KW - Bisphosphonate
UR - http://www.scopus.com/inward/record.url?scp=85033556190&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2017.11.009
DO - 10.1016/j.jconrel.2017.11.009
M3 - Review article
VL - 269
SP - 88
EP - 99
JO - Journal of controlled release
JF - Journal of controlled release
SN - 0168-3659
ER -